As part of the Australian Living Evidence Collaboration, ANZMUSC is helping to produce living guidelines for the management of Arthritis.
An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis
An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis seeks to present the best available, current scientific evidence to assist decision making in the management of JIA. The guideline offers recommended courses of action subject to clinical judgement and patient preferences. They are produced by the Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network, the Australian Rheumatology Association (ARA) and Cochrane Musculoskeletal.
An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis
The objective of this living guideline is to present the best available, current scientific evidence for pharmacological management of the most common forms of IA, namely RA, PsA and axial SpA. Topics and questions identified as having highest clinical relevance to medical practitioners who treat IA are being prioritised. These questions include choice of DMARD, switching, combination therapy, down-titration of treatment and perioperative DMARD use, as well as the management of other medications, such as opioids, glucocorticoids and vaccination. As a living guideline, questions will continue to be addressed, new recommendations developed, and existing recommendations updated on an ongoing basis. Recommendations are intended as guides to courses of action subject to clinical judgement and patient preferences.
Australian clinician guide for the use of immunomodulatory drugs in autoimmune rheumatic diseases at the time of Covid vaccination
This clinician guide has been developed as part of the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis and is designed to be used in conjunction with the recommendations on COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases (AIRD) on immunomodulatory therapies.
It provides general advice, not to replace a shared decision between patient and prescriber given specific clinical circumstances. The guide will be updated as new evidence emerges.
Get involved with ANZMUSC.
Join & Connect with our network and experience the mutual benefit of being part of our group.
Join ANZMUSC
Membership benefits include professional development, networking events, and ability to apply for funding and trial endorsement.
Attend an event
Join us face-to-face or virtually at one of our upcoming events. We have one large annual scientific meeting and also advertise smaller events throughout the year.
Get in touch
Speak to us about the research we are doing, notify us of upcoming events of interest, or enquire about membership.